Shares of Rallybio Corporation RLYB tanked 41.2% on April 8 after the company announced its decision to stop the development of RLYB212 for the prevention of fetal and neonatal alloimmune ...

Overview Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio's shares slumped ahead of the opening bell Tuesday after the clinical-stage biotechnology company dropped its development program on prevention of fetal and neonatal alloimmune ...

RLYB212, an anti-HPA-1a antibody, was in phase 2 development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for ...

The firm’s RLYB212 program was intended to prevent fetal and neonatal alloimmune thrombocytopenia, or FNAIT.

Nipocalimab 15mg/kg improved ClinESSDAI score compared with placebo (treatment difference -2.65; [90% CI, -4.03, -1.28]; P =.002). The Food and Drug Administration (FDA) has granted Breakthrough ...

Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013;161 (1):3-14. doi:10.1111/bjh.12235 Shulman NR, Aster RH, Pearson HA, Hiller MC. Immunoreactions ...

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare hematological disease affecting fetuses and neonates. FNAIT develops during pregnancy when the maternal immune system attacks fetal ...